An interventional study of Oxytocin (OT) and Arginine Vasopressin (AVP) in Healhty, sponsored by University of Electronic Science and Technology of China. Recruiting at 1 site in China. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by University of Electronic Science and Technology of China · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to learn how 24 IU oxytocin (OT) and 24 IU arginine vasopressin (AVP), administered through the oral mucosa, affect attention to emotional faces and related brain activity in healthy adults. The study will compare OT and AVP with a placebo (PLC).
The main questions it aims to answer are:
Participants will:
Oxytocin (OT) and arginine vasopressin (AVP) are neuropeptides involved in social and emotional processing. Previous studies have shown that intranasal OT can modulate top-down and bottom-up attention to emotional faces. Other work has also suggested that OT and AVP may exert both overlapping and distinct effects on social attention. In addition, emerging evidence indicates that oromucosal and intranasal OT administration may produce similar behavioral effects but different neural response patterns. The present study therefore extends previous work by examining the behavioral and neural effects of oromucosally administered OT and AVP within the same emotional attention paradigm.
In a randomized, placebo-controlled, double-blind, between-subject design, healthy adults will receive 24 IU OT, 24 IU AVP, or placebo (PLC) via a lyophilized oromucosal lollipop. Participants will allow the treatment to be absorbed through the oral mucosa for approximately 5 minutes, followed by a 30-minute resting period and post-treatment blood sampling before fMRI scanning.
To control for potential confounding effects and individual differences, participants will complete the Autism Spectrum Quotient, State-Trait Anxiety Inventory, Beck Depression Inventory, and Toronto Alexithymia Scale before treatment administration. Current affective state will be assessed using the Positive and Negative Affect Schedule (PANAS) at three time points: upon arrival at the laboratory, at the beginning of the scanning task, and after completion of the scan.
During fMRI, participants will complete emotional face attention tasks assessing top-down and bottom-up processing under high and low attentional load. Response time, response accuracy, task-evoked BOLD signals, and peripheral neuropeptide levels will be measured to characterize similarities and differences in the effects of OT and AVP on emotional attention.
Exclusion Criteria:
Participants assigned to this arm receive a single 24 IU dose of oxytocin (OT) via a lyophilized oromucosal lollipop, followed by the scheduled post-treatment procedures and fMRI emotional attention tasks.
Drug: Oxytocin (OT)
Participants assigned to this arm receive a single 24 IU dose of arginine vasopressin (AVP) via a lyophilized oromucosal lollipop before completing the fMRI emotional attention tasks.
Drug: Arginine Vasopressin (AVP)
Participants assigned to this arm receive placebo (PLC) via a matched lyophilized oromucosal lollipop before completing the fMRI emotional attention tasks.
Drug: Placebo (PLC)
A single dose of 24 IU oxytocin (OT) is administered via a lyophilized oromucosal lollipop. Participants are instructed to continuously lick the lollipop for approximately 5 minutes to facilitate absorption through the oral mucosa and not to bite, chew, or directly swallow it.
A single dose of 24 IU arginine vasopressin (AVP) is administered via a lyophilized oromucosal lollipop. Participants are instructed to continuously lick the lollipop for approximately 5 minutes to facilitate absorption through the oral mucosa and not to bite, chew, or directly swallow it.
Placebo (PLC), consisting of lyophilized normal saline, is administered via a matched oromucosal lollipop using the same administration procedure as the active treatments. The placebo lollipop is matched to the OT and AVP lollipops in appearance, powder characteristics, and taste.
Behavioral Performance in the Emotional Face Attention Tasks
Behavioral performance will be assessed using correct response time and response accuracy during the emotional face attention tasks. Analyses will examine treatment-related effects across the oxytocin (24 IU), arginine vasopressin (24 IU), and placebo groups within the top-down and bottom-up attention tasks and under high and low attentional load. Primary analyses will evaluate treatment effects and treatment-by-task-condition interactions on reaction time and accuracy. Direct comparisons among OT, AVP, and placebo will be used to characterize shared and differential behavioral effects of the two neuropeptides. For oxytocin, the behavioral effects observed following oromucosal administration will be interpreted with reference to previously reported intranasal findings using the same or a conceptually related attentional framework. Particular emphasis will be placed on whether the direction and condition dependence of effects on reaction time and accuracy show qualitative consistency.
Time frame: During the fMRI task session, approximately 1 hour
BOLD Responses in Predefined Brain Regions and Networks
Task-evoked BOLD responses will be measured using fMRI during the emotional face attention tasks. Primary neuroimaging analyses will examine treatment-related effects within predefined regions of interest and neural networks implicated in emotional salience, attentional control, emotional face processing, and social neuropeptide processing. Regions of interest will be defined independently of the present treatment effects using anatomical definitions and/or prior literature. Treatment effects and treatment-by-task-condition interactions will be assessed across the oxytocin, arginine vasopressin, and placebo groups during top-down and bottom-up attention and under high and low attentional load. Complementary whole-brain analyses will be conducted to identify treatment-related neural effects outside the predefined regions and to characterize broader patterns of task-evoked modulation.
Time frame: During the fMRI task session, approximately 1 hour
Peripheral Oxytocin and Arginine Vasopressin Levels
Peripheral oxytocin and arginine vasopressin concentrations will be measured from blood samples collected before and after treatment administration to assess treatment-related changes in circulating neuropeptide levels.
Time frame: Before treatment administration and approximately 30 minutes after administration
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Electronic Science and Technology of China